secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047220
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M
-------------------------------------------------------------------------

- 2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.
- Q4 2024 revenue of ~$3.5M rose 13% sequentially and 53% YoY; Mytesi prescription volume up 3.9% in 2024.
- Net loss attributable to common shareholders improved to $38.5M from $41.3M in 2023; R&D spend fell $2.1M to $16.5M.
- Expects first proof-of-concept results in Q2 2025 for crofelemer in short bowel syndrome and microvillus inclusion disease trials.
- FDA meeting scheduled Q2 2025 to discuss Phase 3 OnTarget trial results in breast cancer subgroup.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/0000950170-25-047220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/jagx-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer